Board and Committees

Mr Tsai is a former Chairman of Deloitte China and has more than 35 years of experience in planning and managing audits for Hong Kong based operations of multi-national groups, as well as local and overseas listed clients in a wide range of industries. As a Fellow of the Hong Kong Institute of Certified Public Accountants (the “HKICPA”), the Association of Chartered Certified Accountants and the Institute of Chartered Accountants of England and Wales (the “ICAEW”), Mr Tsai is actively involved in the development of the CPA profession and also contributes his efforts in various government, community and social services.

Mr Tsai is a Past President of the HKICPA, a Council Member of the ICAEW, a Member of the Hospital Authority, the Chairman of the Hospital Governing Committee of the Queen Mary Hospital and Tsan Yuk Hospital, the Chairman of the Supplementary Medical Professions Council of the Health Bureau (formerly the Food and Health Bureau), a Member of the Advisory Committee and Audit Committee of the Mandatory Provident Fund Schemes, an Advisor of The Ombudsman, Hong Kong, a Member of the Registration Committee of the Chinese Gold and Silver Exchange, a Member of the Standing Committee on Disciplined Service Salaries and Conditions of Services of the Civil Service Bureau and a Member of the Independent Commission on Remuneration for Members of the Executive Council and the Legislature, and Officials under the Political Appointment System of the HKSAR Government.

Moreover, Mr Tsai is a Member of the University Grants Committee, an Adjunct Professor of the City University of Hong Kong, a Honorary Court Member, the Chairman of the Student Residence Management Board of the Hong Kong Baptist University, the Deputy Chairman of the Alumni Committee of the Hong Kong Baptist University Foundation, a Trustee of the Staff Superannuation Scheme of The Chinese University of Hong Kong and a Member of the Institutional Advancement and Outreach Committee of the University Council of The Hong Kong University of Science and Technology.

Mr Tsai is also the Chairperson of Hong Kong Red Cross.

Professor Liang is a Specialist in Haematology and Haematological Oncology. He is currently Head of Department of Medicine, Director of Comprehensive Oncology Centre and Assistant Medical Superintendent of Hong Kong Sanatorium and Hospital. He is also Emeritus Professor of The University of Hong Kong (HKU) and Honorary Professor of both HKU and The Chinese University of Hong Kong.

Professor Liang was a member of the Hospital Authority Board. Furthermore, he was the Ex-Dean of Li Ka Shing Faculty of Medicine, HKU, and the Past President of the Hong Kong Academy of Medicine.

Professor Liang was one of the founders of Hong Kong Blood Cancer Foundation and Hong Kong Marrow Match Foundation. The latter was responsible for establishing the first all Chinese Unrelated Marrow Donor Registry, serving Chinese patients in need of bone marrow transplantation in Hong Kong, Macau, Taiwan and Mainland China, as well as Chinese patients around the world.

Dr Lo joined Hong Kong Genome Institute (HKGI) as the Chief Executive Officer in March 2021.  As the CEO, Dr Lo leads HKGI in formulating its strategic direction and development plan.  He also provides leadership to the team in launching the Hong Kong Genome Project, the city’s first-ever large-scale whole genome sequencing initiative.  With the aspiration to benefit the wider community, Dr Lo drives the team to be the change agent in fostering clinical application of genomic medicine and its long-term development in Hong Kong.

Dr Lo is a seasoned professional in public health and administrative medicine, bringing with him a wealth of knowledge in public healthcare system, service provision and relevant policies.  He also has a strong blend of experience in corporate affairs, strategic planning, talent development, research and so on.  Prior to his current role, Dr Lo had served in the Hospital Authority (HA) for over 20 years during which he had held various senior management positions, including Director of Strategy & Planning in the HA Head Office and Cluster Chief Executive of the New Territories East Cluster.

In addition to his extensive experience with the HA, Dr Lo also held a number of senior positions both locally and overseas.  These included being the Head of Research Office in the former Food and Health Bureau (currently the Health Bureau) of the HKSAR Government, and the Director of Purchasing (Specialist Care Services) with the Cardiff Health Authority of the National Health Service in the United Kingdom.

Professionally, Dr Lo is a practitioner in Public Health & Administrative Medicine.  He had served as a Part I and II examiner of the Faculty of Public Health, and Censor and examiner of the Royal Australasian College of Medical Administrators.

Mr Chan is the Chief Executive Officer and co-founder of 9GAG, a global multi-platform community for viral content and interests. Founded in 2008, 9GAG’s mission is to make the world happier.

9GAG has a global audience of 200 million, including 56 million followers on Instagram, 42 million followers on Facebook, and 16 million followers on Twitter.

Mr Chan graduated from The University of Hong Kong with a degree in Law.

Professor Chan is the Pro-Vice-Chancellor/Vice President and Li Ka Shing Professor of Biomedical Sciences at The Chinese University of Hong Kong (CUHK). He obtained his BSc (Hon. 1st Class) in Chemistry from CUHK in 1974 and PhD in Biochemistry from the University of Florida in 1977.

In June 2009, Professor Chan established CUHK’s School of Biomedical Sciences and served as the Founding Director and Chair Professor of Biomedical Sciences. He was appointed Pro-Vice-Chancellor/Vice President of CUHK in August 2018.

Professor Chan is very active in the scientific community, both locally and internationally. He has served as President of the Association of Chinese Geneticists in America and a Member of the Development Committee of the Society for the Study of Reproduction in the US. Besides being a Director of the Board of the Hong Kong Genome Institute, he is also the President of Hong Kong Institution of Science, Council Member of the Shaw Prize Foundation, a Member of the Hospital Authority, a Specialist for the Hong Kong Council for Accreditation of Academic and Vocational Qualifications, and a Member of the Board of Directors of Joshua Hellmann Foundation for Orphan Diseases.

Ms Cheung is the Managing Partner and the Head of Audit of KPMG Hong Kong. She was the Past President of the Hong Kong Institute of Certified Public Accountants. She currently serves as member of various public service committees, including the Standing Committee on Disciplined Services Salaries and Conditions of the Service and the Transport Advisory Committee. Apart from being a member of the Advisory Committee, the Honorary Advisory Panel and the Inspection Committee of the Financial Reporting Council, she is the Director of Hong Kong Cyberport Management Company Limited and Insurance Authority.

Ms Cheung has served as Member of the Air Transport Licensing Authority, the Financial Reporting Review Panel, the Independent Commission on Remuneration for Members of the District Councils of the HKSAR, the Non-local Higher and Professional Education Appeal Board, the Occupation Retirement Schemes Appeal Board and the Securities and Futures Appeals Tribunal.

Dr Chung is currently the Director of Quality and Safety of the Hospital Authority (HA). Under his leadership, the Quality & Safety Division oversees the quality standards, patient safety, clinical incident management, patient relations management, healthcare technology assessment, disasters response and infection control for the public hospitals under HA.

Dr Chung is a Specialist in Emergency Medicine. Prior to his current appointment, he has been the Hospital Chief Executive of North District Hospital from 2016 to 2018, Chief Manager at HA Head Office from 2012 to 2016 and the Hospital Chief Executive of Castle Peak Hospital from 2008 to 2012.

Professor Lau is Dean and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the Li Ka Shing Faculty of Medicine at The University of Hong Kong (HKU).

Professor Lau graduated with MBChB from the University of Dundee in 1985. In 1992, he joined HKU as Lecturer in Medicine and successfully rose through the ranks to his current position as Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology.

Professor Lau has been a major player in rheumatology in Hong Kong and beyond. Locally, he was President of the Hong Kong Society of Rheumatology (1997 – 2001) and Founding Chairman of the Hong Kong Arthritis & Rheumatism Foundation (2001). He was also the President of the Hong Kong Academy of Medicine (2016 – 2020), a statutory accrediting body for medical and dental specialist training in Hong Kong. Besides its academic role, the Academy is an entrusted advisor to the HKSAR Government on multiple health-related policies. In addition, Professor Lau sits on numerous strategic committees/working groups of the Health Bureau (formerly the Food and Health Bureau), Hospital Authority and Department of Health.

Regionally, Professor Lau was President of the Asia Pacific League of Rheumatology Associations (2006 – 2008) and co-founder of the multi-national, multi-centre Asia Pacific Lupus Collaboration.

Beyond the Asia Pacific region, he is a Member of the Outcomes in Rheumatology, European League Against Rheumatism (EULAR) Scientific Committee and EULAR Task Force on Rheumatoid Arthritis Treatment Recommendations.

Dr Leung is the founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited.

Dr Leung has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of “Functional Humanisation”. Dr Leung currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology, The Army Medical University (formerly known as the Third Military Medical University) and The Air Force Medical University (formerly known as the Fourth Military Medical University) in Mainland China. He held positions as the Executive Director of a leading US antibody-drug conjugate company, the Managing Director of The Hong Kong Institute of Biotechnology Limited, as well as the Adjunct Professor at Fudan University and The Chinese University of Hong Kong (CUHK).

Dr Leung obtained his BSc and MPhil in biochemistry, as well as EMBA from CUHK. He earned his D.Phil. in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1989 to June 1991.

Dr Liu is the Head of Baker McKenzie’s Asia Pacific Intellectual Property (IP) and Technology Group. She advises clients on matters relating to the creation, exploitation and protection of IP rights. She is also responsible for the local IP Group’s China and Hong Kong patent prosecution matters. Previously, Dr Liu was the Head of the Firm’s Asia Pacific Healthcare and Life Sciences Industry Group for three years, leading a team of legal experts in this field cross multiple practices in the region.

Dr Liu is ranked as a leading lawyer in her field by top legal directories such as Chambers Asia Pacific for the Life Sciences category and IAM Patent. She has been complimented by clients that she possesses “a superb ability to understand the most complex technologies” and was noted for “advis[ing] in a way that is very commercial and strategic.”

Professor Lo is the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong. His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer.

In recognition of his research, Professor Lo has been elected as Fellow of the Royal Society, Foreign Associate of the US National Academy of Sciences, Fellow of The World Academy of Sciences and Founding Member of the Academy of Sciences of Hong Kong. He has won numerous awards, including the 2016 Future Science Prize in Life Science, the 2014 King Faisal International Prize in Medicine, the 2019 Fudan-Zhongzhi Science Award and the 2021 Breakthrough Prize in Life Sciences.

Professor Ngan is currently Kingboard Professor in Materials Engineering and Chair Professor of Materials Science and Engineering at The University of Hong Kong (HKU). He previously held administrative positions including Senior Advisor in the President’s Office, Acting Pro-Vice Chancellor (Research), Head of Department of Mechanical Engineering and Associate Dean of Engineering. He obtained his BSc(Eng) degree from HKU in 1989, and PhD from the University of Birmingham in the UK in 1992. After a year of postdoctoral training at the University of Oxford, he joined HKU in 1993, and was promoted through the ranks to Chair Professorship in 2011.

Professor Ngan’s interest includes novel stimuli-responsive materials, material defects and their modelling, and nanomechanics including applications to biological systems. His research-related honours include the Rosenhain Medal from the Institute of Materials, Minerals and Mining in the UK, DSc from the University of Birmingham, Croucher Senior Research Fellowship, International Fellow of the Royal Academy of Engineering (FREng), Fellow of the Hong Kong Academy of Engineering Sciences (FHKEng), and Guanghua Engineering Science and Technology Prize. He is currently Honorary Secretary of the Hong Kong Academy of Engineering Sciences, and is serving in a number of advisory/management boards in the HKSAR Government.

Mr Wong is currently a practising barrister, an arbitrator of Shanghai Arbitration Commission and a qualified dispute resolver of Academy of Experts (London).  He had graduated from The University of Hong Kong before he was awarded with a Government Legal Scholarship to further his studies and professional training in the United Kingdom.  Mr Wong obtained his Master in Laws (Intellectual Property, Marine Business and Insurance, Civil Litigation) from the London School of Economics and Political Science, as well as the qualification of a practising solicitor from the Supreme Court of England and Wales.

Upon return to Hong Kong, Mr Wong joined the then Attorney General’s Chambers as a Crown Counsel, and assumed various posts including Assistant Director of Public Prosecutions, Head of China Law and Basic Law, Deputy Solicitor-General, Secretary-General of the Law Reform Commission and Privacy Commissioner.  Since 2020, he has been a Barrister-at-Law in private practice, focusing on International Public Law, Data and Information Law, Innovation, Communications and Technology, Civil and Commercial Law, Company, Trust and Economic Criminal Law by providing professional legal advice and court advocacy services to local, mainland and overseas public, private and multi-national organisations, as well as small and medium-size enterprises.

Current community services Mr Wong undertakes include Member of the HKSAR Election Committee (Legal), Director of China Law Society, Expert Member of Shenzhen Municipal Law Compliance Commission, Expert Member of FinTech Committee of Asian Financial Cooperation Association, Adjunct Law Professor of Beijing Normal University, Chairman of the Independent Vetting Committee of Hong Kong Institute of Big Data, Executive Committee Member of Hong Kong International Law Association and Honorary Adviser of Hong Kong Institute of Bankers.

Mr Wong’s publications include two works on Hong Kong Privacy Law (one published in English and the other in Chinese language), and chapters on data related issues in international medical and health journals.

Mr Pang is a registered social worker dedicated in protecting and advocating patient’s rights. He works as Community Organizer in Society for Community Organization. He has been a Member of the Hospital Authority (HA) Review Steering Committee, a Member of the Patient Focus Group of the Hospital Accreditation Project under HA, and a Member of the Committee on Promoting Acceptance of People Living with HIV/AIDS under Hong Kong Advisory Council on AIDS.

Mr Pang is now a Member of the Working Group on Implementation of Modified Referral System for Physiotherapy Services under the Physiotherapists Board, and a Member of the Working Group on eHRSS Partnership under the Steering Committee on Electronic Health Record Sharing.

Professor Wong is the Dean of Science and Chair Professor of Life Science at The Hong Kong University of Science and Technology (HKUST).  He also serves as the Director of the Molecular Neuroscience Center, and as an Associate Director of the Biotechnology Research Institute and the Center for Aging Science at HKUST.

Professor Wong obtained his PhD in Pharmacology from the University of Cambridge and conducted postdoctoral training at the University of California San Francisco.  Since joining HKUST, his research has been focused on the delineation of the mechanisms of cell signalling, particularly those involving drug receptors.  Professor Wong has integrated his scientific endeavours into drug discovery and development in collaboration with pharmaceutical companies.

As an accomplished researcher, he has published over 220 scientific articles and received a number of awards, including the Croucher Senior Research Fellowship and the Medal of Honor.  Over the years, Professor Wong had served as a member of the Medical Council of Hong Kong, the Consumer Council of Hong Kong, and the Research Grants Council of Hong Kong (Biology and Medicine Panel).

He is currently serving in the Sir Edward Youde Memorial Fund Council and the Advisory Board of Hong Kong Life Sciences Society. Professor Wong is also a consultant for The Hong Kong Science and Technology Parks Corporation, multinational companies, and local secondary schools to promote biotechnology.

Professor Yiu is currently a professor and one of the Associate Heads at the Department of Computer Science of The University of Hong Kong (HKU). He is also the Director of the Department’s FinTech and Blockchain Laboratory and the Deputy Executive Director of HKU–Standard Chartered Hong Kong FinTech Academy. He was selected three times by Clarivate Analytics as one of the Highly Cited Researchers in the world in 2016, 2017 and 2019, and one of the top 1% researchers in HKU for 11 consecutive years (2011 – 2021).

Professor Yiu’s research areas include bioinformatics, cybersecurity, privacy technology, and FinTech. In the areas of bioinformatics, he served as the conference chair in Hong Kong for RECOMB 2017, one of the flag-ship conferences in the field and as the area programme chair for other prestigious bioinformatics conferences such as ISMB. In addition to academic research, Professor Yiu has been a consultant to various companies in the areas of cybersecurity and data privacy.

Mr Choi is currently the Deputy Secretary for Health, responsible for formulation of policies on medical services and healthcare system and infrastructure, including matters relating to public health, prevention of communicable diseases, operation and development of public and private hospitals, healthcare financing (including Voluntary Health Insurance Scheme), research and health data as well as genomic medicine development.

Prior to this appointment, Mr Choi was the Deputy Secretary for Transport and Housing from 2017 to 2020, and the Deputy Director-General of Civil Aviation from 2016 to 2017.

Dr Li is a specialist in Public Health Medicine and currently the Deputy Director of Health. She oversees areas related to health services and administration including elderly health, family and student health, specialised services, administration and policy, finance, health administration and planning, and health information and technology.